Summary

For patients with diabetes who undergo percutaneous coronary intervention (PCI), drug-eluting stents (DES) reduce the risk of mortality, acute myocardial infarction (MI), and repeat revascularization compared with bare-metal stents (BMS). These 3-year findings from the Massachusetts Data Analysis Center Registry (Mass-DAC), which requires mandatory reporting and follow-up, reflect achievable treatment outcomes in the real-world clinical setting, researchers reported.